Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.6K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.6K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

127
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
127
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

191
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
191
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

249
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
249
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

141
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
141
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

676
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
676

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OX40 transcriptomic expression and its association with immune checkpoints and clinical outcomes.

Therapeutic advances in medical oncology·2026
Same author

Soft-tissue sarcoma with MN1-BEND2 fusion: second reported case and comparative analysis.

Journal of surgical case reports·2026
Same author

Staged Resection with Temporizing VAC and Local Recurrence for Soft Tissue Sarcomas: A Multi-Institutional Review.

Cancers·2026
Same author

Mitochondria-targeted agents disrupt bioenergetics in parasitic nematodes.

Archives of biochemistry and biophysics·2026
Same author

Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer.

Cancers·2026
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026

Related Experiment Video

Updated: Nov 25, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.6K

Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.

Sherry-Ann Brown1, Svetlana Zaharova1, Peter Mason2

  • 1Cardio-Oncology Program, Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.

Frontiers in Cardiovascular Medicine
|December 21, 2020
PubMed
Summary

Cardio-oncology and COVID-19 share cardiovascular toxicities, pathophysiology, and pharmacology. Understanding these overlaps offers insights into both conditions, improving patient care and addressing health disparities.

Keywords:
COVID-19cardio-oncologycytokine release syndromehealth disparitiesinflammationpandemicright ventricletelemedicine

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.0K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

Related Experiment Videos

Last Updated: Nov 25, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.6K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.0K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

Area of Science:

  • Cardiology
  • Oncology
  • Infectious Diseases
  • Pharmacology

Background:

  • The COVID-19 pandemic revealed significant overlaps with cardio-oncology, particularly concerning cardiovascular toxicities (CVT).
  • Patients with pre-existing cardiovascular disease (CVD), its risk factors, or cancer face a higher risk of severe COVID-19.
  • Shared pathophysiological mechanisms include inflammation, cytokine release, and endothelial dysfunction.

Purpose of the Study:

  • To explore commonalities in cardiovascular toxicities between COVID-19 and cardio-oncology.
  • To investigate shared underlying pathophysiology and pharmacological management strategies.
  • To highlight future directions and health equity considerations in cardio-oncology.

Main Methods:

  • Perspective review of existing literature on COVID-19 and cardio-oncology.
  • Analysis of shared cardiovascular toxicities: cardiomyopathy, ischemia, conduction abnormalities, myopericarditis, and right ventricular failure.
  • Examination of commonalities in inflammation, cytokine release, renin-angiotensin-aldosterone system, coagulopathy, microthrombosis, and endothelial dysfunction.

Main Results:

  • Identified significant overlaps in CVT, including cardiomyopathy, ischemia, and heart failure, between COVID-19 and cardio-oncology.
  • Highlighted shared pathophysiological pathways such as inflammation, cytokine storm, and endothelial dysfunction.
  • Discussed common pharmacologic strategies, including corticosteroids and ACE inhibitors/ARBs, and their relevance in both fields.

Conclusions:

  • COVID-19 and cardio-oncology exhibit substantial overlap in cardiovascular toxicity, pathophysiology, and pharmacology.
  • Further research into these shared areas can provide mutual insights and improve patient outcomes.
  • Addressing health disparities is crucial for equitable care in both COVID-19 and cardio-oncology.